news
mRNA vaccine candidates for HIV enter Phase I trial
Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.
List view / Grid view
The Scripps Research Institute
news
First patients dosed in HIV vaccine immunogens trial
Moderna and IAVI take steps towards HIV vaccination, with initiation of a trial dosing patients with HIV immunogens delivered by mRNA.
news
Scientists call for investment into novel, potentially pan-virus vaccines to prevent the next pandemic
Investment into vaccines based on broadly neutralising antibodies could allow pan-virus vaccines to be developed and stockpiled before the next pandemic, say researchers.
news
Heroin vaccine blocks lethal overdose
Scientists have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug...
news
Dietary xenoestrogens may reduce effectiveness of breast cancer treatment
A new study suggests breast cancer patients taking palbociclib/letrozole combination therapy should avoid foods rich in xenoestrogens...
news
Ozanimod successful in clinical trials for multiple sclerosis
The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...
article
Small non-coding RNAs as therapeutics
20 March 2009 | By
For years biologists have worked to develop alternatives to traditional therapeutics. These efforts, in areas such as stem cell based and gene therapies, have received much fanfare in popular media outlets, raising expectations among the general public. This excitement may have contributed to the hasty progression of early gene therapy…
article
HUPO drives the creation of protein test standards
28 November 2006 | By John R. Yates, III, Department of Cell Biology, The Scripps Research Institute, Thierry Rabilloud, DBMS/BMCC, Alexander W. Bell, Montreal Proteomics Centre, McGill University and John J. M. Bergeron, Department of Anatomy and Cell Biology, McGill University, Quebec
Over the last ten years the Proteomics field has been a technologically dynamic area. New methods and techniques help drive the field to achieve more sophisticated measurements that yield increasingly larger volumes of data and information. This creates several problems.
